Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$206.12 -1.0%	$214.17	$176.57 ▼ $244.81	$368.06B	0.32	6.94 million shs	4.48 million shs
ABT Abbott Laboratories	$87.18 -0.4%	$103.83	$86.16 ▼ $139.06	$152.48B	0.65	13.46 million shs	17.19 million shs
AMGN Amgen	$329.59 +1.8%	$357.16	$261.43 ▼ $391.29	$174.78B	0.44	2.62 million shs	3.32 million shs
PFE Pfizer	$26.42 +0.5%	$27.17	$21.97 ▼ $28.75	$149.55B	0.35	34.14 million shs	56.09 million shs
REGN Regeneron Pharmaceuticals	$702.45 -1.0%	$755.26	$476.49 ▼ $821.11	$74.98B	0.3	737,661 shs	642,637 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.25%	+4.19%	-1.28%	-5.03%	+5.14%
ABT Abbott Laboratories	-2.61%	-7.06%	-15.23%	-19.42%	-34.22%
AMGN Amgen	-0.07%	-2.94%	-5.27%	-10.00%	+17.69%
PFE Pfizer	+0.29%	-0.09%	-6.85%	-1.52%	+10.73%
REGN Regeneron Pharmaceuticals	+0.15%	-4.01%	-7.80%	-9.39%	+16.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABBV AbbVie	$206.12 -1.0%	$214.17	$176.57 ▼ $244.81	$368.06B	0.32	6.94 million shs	4.48 million shs
ABT Abbott Laboratories	$87.18 -0.4%	$103.83	$86.16 ▼ $139.06	$152.48B	0.65	13.46 million shs	17.19 million shs
AMGN Amgen	$329.59 +1.8%	$357.16	$261.43 ▼ $391.29	$174.78B	0.44	2.62 million shs	3.32 million shs
PFE Pfizer	$26.42 +0.5%	$27.17	$21.97 ▼ $28.75	$149.55B	0.35	34.14 million shs	56.09 million shs
REGN Regeneron Pharmaceuticals	$702.45 -1.0%	$755.26	$476.49 ▼ $821.11	$74.98B	0.3	737,661 shs	642,637 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABBV AbbVie	-0.25%	+4.19%	-1.28%	-5.03%	+5.14%
ABT Abbott Laboratories	-2.61%	-7.06%	-15.23%	-19.42%	-34.22%
AMGN Amgen	-0.07%	-2.94%	-5.27%	-10.00%	+17.69%
PFE Pfizer	+0.29%	-0.09%	-6.85%	-1.52%	+10.73%
REGN Regeneron Pharmaceuticals	+0.15%	-4.01%	-7.80%	-9.39%	+16.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABBV AbbVie	2.85	Moderate Buy	$252.90	22.70% Upside
ABT Abbott Laboratories	2.88	Moderate Buy	$119.43	37.00% Upside
AMGN Amgen	2.42	Hold	$357.12	8.35% Upside
PFE Pfizer	2.23	Hold	$28.74	8.77% Upside
REGN Regeneron Pharmaceuticals	2.77	Moderate Buy	$826.59	17.67% Upside

Current Analyst Ratings Breakdown

Latest ABT, ABBV, AMGN, PFE, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/5/2026	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/4/2026	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$351.00 ➝ $340.00
5/1/2026	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$332.00
5/1/2026	ABBV AbbVie	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$249.00
5/1/2026	AMGN Amgen	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$325.00 ➝ $327.00
5/1/2026	AMGN Amgen	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$415.00 ➝ $425.00
5/1/2026	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$975.00 ➝ $995.00
4/30/2026	ABBV AbbVie	DZ Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/30/2026	ABBV AbbVie	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$262.00 ➝ $265.00
4/30/2026	ABBV AbbVie	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$270.00 ➝ $278.00
4/30/2026	ABBV AbbVie	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$240.00

(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABBV AbbVie	$61.16B	5.96	$15.00 per share	13.74	($1.83) per share	-112.63
ABT Abbott Laboratories	$44.33B	3.43	$6.96 per share	12.52	$30.26 per share	2.88
AMGN Amgen	$36.75B	4.84	$34.40 per share	9.58	$17.03 per share	19.35
PFE Pfizer	$62.58B	2.40	$4.42 per share	5.98	$15.26 per share	1.73
REGN Regeneron Pharmaceuticals	$14.34B	5.18	$41.56 per share	16.90	$297.23 per share	2.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABBV AbbVie	$4.23B	$2.03	101.54	12.68	0.72	5.79%	-911.57%	13.43%	N/A
ABT Abbott Laboratories	$6.52B	$3.57	24.42	14.39	1.46	13.90%	17.62%	10.01%	7/16/2026 (Estimated)
AMGN Amgen	$7.71B	$14.37	22.94	14.07	3.08	20.96%	137.41%	13.28%	N/A
PFE Pfizer	$7.77B	$1.36	19.43	9.37	N/A	12.42%	20.48%	8.86%	N/A
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	17.12	16.92	1.58	29.65%	13.16%	10.17%	N/A

Latest ABT, ABBV, AMGN, PFE, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion
4/30/2026	Q1 2026	AMGN Amgen	$4.77	$5.15	+$0.38	$3.34	$8.58 billion	$8.62 billion
4/29/2026	Q1 2026	ABBV AbbVie	$2.59	$2.65	+$0.06	$0.39	$14.72 billion	$15.00 billion
4/29/2026	Q1 2026	REGN Regeneron Pharmaceuticals	$8.91	$9.47	+$0.56	$6.75	$3.48 billion	$3.61 billion
4/16/2026	Q1 2026	ABT Abbott Laboratories	$1.14	$1.15	+$0.01	$0.61	$10.99 billion	$11.16 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABBV AbbVie	$6.92	3.36%	+6.80%	340.89%	53 Years
ABT Abbott Laboratories	$2.52	2.89%	+10.39%	70.59%	54 Years
AMGN Amgen	$10.08	3.06%	+8.27%	70.15%	14 Years
PFE Pfizer	$1.72	6.51%	-13.20%	126.47%	16 Years
REGN Regeneron Pharmaceuticals	$3.76	0.54%	N/A	9.16%	N/A

Latest ABT, ABBV, AMGN, PFE, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2026	PFE Pfizer	quarterly	$0.43	6.42%	5/8/2026	5/8/2026	6/12/2026
3/4/2026	AMGN Amgen	quarterly	$2.52	2.66%	5/15/2026	5/15/2026	6/5/2026
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.55%	5/20/2026	5/20/2026	6/4/2026
2/19/2026	ABBV AbbVie	quarterly	$1.73	3.32%	4/15/2026	4/15/2026	5/15/2026
2/20/2026	ABT Abbott Laboratories	quarterly	$0.63	2.48%	4/15/2026	4/15/2026	5/15/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABBV AbbVie	N/A	0.67	0.56
ABT Abbott Laboratories	0.56	1.39	1.01
AMGN Amgen	5.65	1.26	0.90
PFE Pfizer	0.71	1.16	0.87
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABBV AbbVie	70.23%
ABT Abbott Laboratories	75.18%
AMGN Amgen	76.50%
PFE Pfizer	68.36%
REGN Regeneron Pharmaceuticals	83.31%

Insider Ownership

Company	Insider Ownership
ABBV AbbVie	0.06%
ABT Abbott Laboratories	0.46%
AMGN Amgen	0.85%
PFE Pfizer	0.62%
REGN Regeneron Pharmaceuticals	6.97%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABBV AbbVie	57,000	1.77 billion	1.77 billion	Optionable
ABT Abbott Laboratories	115,000	1.74 billion	1.73 billion	Optionable
AMGN Amgen	31,500	539.68 million	535.10 million	Optionable
PFE Pfizer	75,000	5.69 billion	5.65 billion	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable

ABT, ABBV, AMGN, PFE, and REGN Headlines

Recent News About These Companies

Regeneron (REGN) Dupixent Phase 4 Trial Results Show Improved Esophageal Function in EoE

May 5 at 1:24 PM | investorshub.advfn.com

Varma Mutual Pension Insurance Co Sells 2,800 Shares of Regeneron Pharmaceuticals, Inc. $REGN

May 5 at 8:34 AM | marketbeat.com

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

May 5 at 8:23 AM | finance.yahoo.com

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

May 5 at 7:00 AM | globenewswire.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Horizon Investments LLC

May 5 at 5:52 AM | marketbeat.com

Arthur Ryan Sells 100 Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) Stock

May 5 at 5:23 AM | insidertrades.com

Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells 100 Shares of Stock

May 4 at 4:50 PM | marketbeat.com

How The Regeneron (REGN) Narrative Is Shifting With Dupixent, Eylea And Pipeline Developments

May 4 at 7:55 AM | finance.yahoo.com

Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Seizert Capital Partners LLC

May 4 at 7:03 AM | marketbeat.com

Kornitzer Capital Management Inc. KS Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN

May 4 at 6:28 AM | marketbeat.com

Bellecapital International Ltd. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

May 4 at 3:31 AM | marketbeat.com

PKO Investment Management Joint Stock Co Has $3.74 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

May 3 at 7:54 AM | marketbeat.com

Strs Ohio Sells 2,589 Shares of Regeneron Pharmaceuticals, Inc. $REGN

May 3 at 7:13 AM | marketbeat.com

PFA Pension Forsikringsaktieselskab Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

May 3 at 7:00 AM | marketbeat.com

Fifth Third Bancorp Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN

May 3 at 4:31 AM | marketbeat.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of "Moderate Buy" from Brokerages

May 3 at 2:53 AM | americanbankingnews.com

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Average Recommendation of "Moderate Buy" by Analysts

May 3 at 2:17 AM | marketbeat.com

Piper Sandler Rates Regeneron (REGN) Overweight on Oncology Growth

May 2, 2026 | finance.yahoo.com

Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?

May 2, 2026 | fool.com

Del Sette Capital Management LLC Acquires New Shares in Regeneron Pharmaceuticals, Inc. $REGN

May 2, 2026 | marketbeat.com

Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Upgraded by Wall Street Zen

May 2, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ABT, ABBV, AMGN, PFE, and REGN Company Descriptions

AbbVie NYSE:ABBV

$206.12 -2.04 (-0.98%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$206.00 -0.12 (-0.06%)

As of 05/5/2026 07:59 PM Eastern

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Abbott Laboratories NYSE:ABT

$87.18 -0.36 (-0.42%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$87.30 +0.12 (+0.14%)

As of 05/5/2026 07:58 PM Eastern

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Amgen NASDAQ:AMGN

$329.59 +5.74 (+1.77%)

Closing price 05/5/2026 04:00 PM Eastern

Extended Trading

$329.50 -0.09 (-0.03%)

As of 05/5/2026 07:55 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Pfizer NYSE:PFE

$26.42 +0.12 (+0.46%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$26.50 +0.07 (+0.28%)

As of 05/5/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Regeneron Pharmaceuticals NASDAQ:REGN

$702.45 -6.76 (-0.95%)

Closing price 05/5/2026 03:59 PM Eastern

Extended Trading

$703.96 +1.51 (+0.21%)

As of 05/5/2026 07:50 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABT, ABBV, AMGN, PFE, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABT, ABBV, AMGN, PFE, and REGN Earnings

Compare Dividends

Latest ABT, ABBV, AMGN, PFE, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABT, ABBV, AMGN, PFE, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ABT, ABBV, AMGN, PFE, and REGN Company Descriptions

AbbVie NYSE:ABBV

Abbott Laboratories NYSE:ABT

Amgen NASDAQ:AMGN

Pfizer NYSE:PFE

Regeneron Pharmaceuticals NASDAQ:REGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools